Dividend Stocks

The Dividend Daily

Dividend stocks - News, notes, updates, and analysis, delivered fresh daily

Johnson & Johnson Expects 4 Cent Q1 EPS Hit From Venezuelan Currency Devaluation (JNJ)

Another company, health care products maker Johnson & Johnson (JNJ), said on Monday that the currency devaluation in Venezuela will have a negative impact on upcoming earnings.

The New Brunswick, New Jersey-based company said that it will take a charge of $100 million in the first quarter of 2013 as a result of Venezuela’s currency devaluation. This equates to a negative impact of 4 cents per share to first quarter EPS.

JNJ’s hefty charge is related to the re-measurement of the local balance sheet. Despite the charge and the negative impact it will have on first quarter earnings results, it is not expected to impact the company’s full year outlook which was previously announced in January.

Johnson & Johnson shares were relatively flat during pre-market trading on Monday. The stock is up +18.29% over the past year.

The Bottom Line
Shares of Johnson & Johnson (JNJ) have a dividend yield of 3.20% based on Friday’s closing price of $76.25 and the company’s annualized dividend payout of $2.44 per share.

Johnson & Johnson (JNJ) is recommended at this time, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks, as well as a detailed explanation of our ratings system here.

5 Rules of Winning Dividend Investing

FREE Dividend Stock Newsletter

Get the Dividend.com email newsletter to receive:

  • A free copy of our acclaimed report, 5 Rules of Winning Dividend Stock Investing
  • Free daily investing tips and picks from Dividend.com CEO Paul Rubillo
  • Tons of great market analysis and recommendations

Your Email

Free Dividend Newsletter

Get free dividend tips, analysis and updates straight to your inbox

Comments on this Article COMMENTS ON THIS ARTICLE

Comments are closed.

About This Article ABOUT THIS ARTICLE

You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Disclaimer: Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. The author is not registered as an investment adviser. The author may or may not hold positions in the securities mentioned in this article or video. The author relies upon the "publisher's exclusion" from the definition of "investment adviser" as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.